BioStock: Saniona trailblazing towards market approval

Saniona, currently redeeming the first out of three outstanding warrants, is approaching late-stage clinical studies with lead candidate Tesomet in two eating disorder indications. Meanwhile, partner company Medix is getting ready to launch its licensed asset tesofensine as a new obesity drug following a successful phase III study in Mexico. BioStock had a talk with Saniona’s US based CEO Rami Levin, who after 23 years in the industry will use his experience to attract major US biotech investors to the company. 

Read the full interview with Rami Levin at biostock.se:

https://www.biostock.se/en/saniona-trailblazing-towards-market-approval/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se